Immunity APC and Open Access: Cell Press Pricing, Limited Institutional Coverage, and What You'll Actually Pay

Immunity operates as a hybrid journal:

1. Subscription track (default, $0): Your article appears behind the Cell Press paywall. Readers access it through institutional subscriptions. You pay nothing.
2. Gold open access track ($9,350): Your article is immediately free to read for everyone under a Creative Commons license.

The subscription route is the default, and it's what most Immunity authors choose. Your paper still gets the same DOI, the same indexing in PubMed and Web of Science, and the same editorial prestige. The only difference is whether a reader without a subscription can access the full text.

This is where publishing in a Cell Press journal gets frustrating. Elsevier has negotiated transformative agreements with hundreds of institutions worldwide. These agreements cover APCs for over 1,800 Elsevier "core hybrid journals." But the fine print excludes Cell Press titles, along with Lancet and Clinics journals.

What this means for you:

A small number of institutions have negotiated separate Cell Press inclusion. The University of California system's Elsevier agreement was expanded in 2025 to include Cell Press and Lancet titles, with the library covering a portion of the APC. But this is the exception. Most Elsevier agreements still exclude Cell Press.

Before committing to OA at Immunity, contact your library and ask specifically: "Does our Elsevier agreement cover Cell Press journals?" Don't assume it does because other Elsevier journals are covered.

Cell Press has a less transparent waiver system than Springer Nature or BMJ:

Geographical pricing (GPOA):

Elsevier's Geographical Pricing for Open Access program applies to Immunity. Authors from lower-income countries receive discounted APCs based on Elsevier's internal country tier system. Discounts range from 25% to 100% off, calculated automatically during the payment process based on your institutional affiliation.

Unlike Springer Nature's straightforward Research4Life waiver (full waiver for Group A, 50% for Group B), Elsevier's GPOA uses a proprietary tiering system that's less predictable. The system generates a "personalized APC" at the payment stage.

Financial hardship waivers:

Case-by-case waivers are available. If you can't afford the APC and have no institutional or funder support, contact the editorial office after acceptance. Approval is not guaranteed, and the success rate for hardship waivers at Cell Press is not publicly disclosed.

No society membership discounts:

The American Association of Immunologists (AAI), which publishes The Journal of Immunology, does not have a discount arrangement with Cell Press. AAI membership doesn't reduce your Immunity APC.

Immunity supports both CC BY and CC BY-NC-ND licenses for open access articles. Plan S requires CC BY. If your funder is a cOAlition S member, you must select CC BY during the licensing stage. The CC BY-NC-ND option does not satisfy Plan S.

For NIH-funded researchers, the green route is available: publish via subscription for free, then deposit the accepted manuscript in PubMed Central after a 12-month embargo. This is the most common path for US immunologists who don't want to pay $9,350 out of pocket.

The 12-month embargo clock starts from the publication date, not the acceptance date. Papers that spend several months in production have a longer total wait before they appear in PMC.

Immunity has a clear editorial identity that shapes what gets accepted. The journal publishes across immunology, but it has particular strengths:

• Mechanistic immunology: Papers that define new signaling pathways, transcription factor networks, or cell fate decisions in immune cells. This is Immunity's bread and butter.

• T cell biology: The journal has historically been particularly strong in adaptive immunity, especially T cell differentiation, exhaustion, and memory.

• Innate immunity: Pattern recognition, inflammasomes, and innate immune cell development.

• Immunometabolism: Immunity was an early champion of the immunometabolism field and continues to publish leading work here.

The journal desk-rejects a large fraction of submissions. Immunity receives over 3,000 submissions annually and publishes roughly 200 articles, giving it an acceptance rate around 6-7%. The editorial team looks for papers that provide mechanistic insight into immune processes, not just descriptive or correlative findings.

Immunity was founded in 1994 as a sister journal to Cell. It's published monthly, with each issue typically containing 10-15 articles. The journal's prestige in the immunology community is second only to Nature Immunology, and some immunologists consider the two interchangeable in terms of impact.

Immunity doesn't charge submission fees, page fees, or color figure surcharges. But be aware of these:

• Tax: VAT or sales tax applies in many jurisdictions and is added on top of the $9,350 APC. In the EU, expect 15-25% additional cost. A $9,350 APC can become $11,000+ after tax.

• Graphical abstract: Cell Press journals require a graphical abstract for all research articles. If you hire a scientific illustrator, budget $200-$500. You can create one yourself, but Cell Press has specific formatting requirements.

• License lock-in: If you select CC BY-NC-ND and later realize your funder requires CC BY, changing the license post-publication is difficult and not guaranteed.

• Embargo timing: For the green OA route, the 12-month PMC embargo starts at publication, not acceptance. Production delays extend the total wait.

• Revision costs: Immunity often requests extensive revisions, including new experiments. The cost of additional experiments is not a journal fee, but it's a real cost. Revision periods at Immunity can stretch to 3-6 months and may require significant lab resources.

Immunity's APC puts it in an awkward spot. It's too expensive for researchers without institutional coverage or large grants, but it lacks the institutional safety net that makes similar-priced journals more accessible.

Here's the decision framework:

1. Does your Elsevier agreement cover Cell Press? Ask your library. If yes, choose OA. If no (the likely answer), proceed to step 2.
2. Does your grant cover the APC? Many NIH R01s and ERC grants include publication cost budgets. Check whether $9,350 fits. Remember to add tax.
3. Does your funder mandate immediate OA? If yes, you need gold OA and the $9,350 fee. If not, use the subscription track for free.
4. No mandate, no coverage? Publish via subscription. Your paper is still in Immunity with the same prestige and visibility within the field.

For many immunologists, the subscription track is the pragmatic choice. The field still values journal name and impact factor far more than access model, and Immunity's institutional subscriber base ensures that other immunologists can read your work.

Getting into Immunity is harder than paying for it. The journal's 6-7% acceptance rate means your manuscript needs to present a mechanistic advance that changes how immunologists think about a process. Immunity submission readiness check to check your paper's fit before submitting. For a look at Cell Press pricing across the portfolio, see our Cell APC breakdown.

Worth paying if:

• Your funder mandates open access (check Plan S / cOAlition S requirements)
• An institutional Read & Publish agreement covers the fee
• Open access visibility meaningfully benefits your research area
• The APC fits within your grant budget

Consider alternatives if:

• The APC is a personal out-of-pocket expense
• A subscription option or green OA (preprint + embargo) satisfies your funder
• Another OA journal with a lower APC would provide similar visibility